

<b>Form PTO-1449</b>  <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DKT. NO.</b> BAYER 15P3	<b>SERIAL NO.</b> TO BE ASSIGNED
	<b>APPLICANT</b> Bernd RIEDL et al.	
	<b>FILING DATE</b> February 7, 2001	<b>GROUP</b> TO BE ASSIGNED

09/777920  
 02/07/01

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
RO	AA	3,823,161	07/09/74	Lesser		
RO	AB	5,130,331	07/14/92	Pascual		
RO	AC	4,808,588	02/28/89	King		
RO	AD	3,424,760	01/28/69	Helsley et al.		
RO	AE	3,424,761	01/28/69	Helsley et al.		
RO	AF	3,424,762	01/28/69	Helsley et al.		
RO	AG	4,071,524	01/31/78	Banitt		
RO	AH	4,111,683	09/05/78	Singer		
RO	AI	4,437,878	03/20/78	Acker et al.		
RO	AJ	4,643,849	02/17/87	Hirai et al.		
RO	AK	5,773,459	06/30/98	Tang et al.		
RO	AL	5,508,288	04/16/96	Forbes et al.		
RO	AM	4,062,861	12/13/77	Yukinaga et al.		
RO	AN	4,111,680	09/05/78	Yukinaga et al.		
RO	AO	4,116,671	09/26/78	Yukinaga et al.		
RO	AP	4,212,981	07/15/80	Yukinaga et al.		
RO	AQ	5,162,360	11/10/92	Creswell et al.		
RO	AR	4,514,571	04/30/85	Nakai et al.		
RO	AS	3,754,887	08/28/73	Brantley		
RO	AT	3,646,059	02/29/72	Brantley		
RO	AU	5,696,138	12/9/97	Olesen et al.		
RO	AV	5,780,483	7/14/98	Widdowson et al.		
RO	AW	4,405,644	9/20/83	Kabbe et al.		
RO	AX	4,473,579	9/25/84	Devries et al.		
RO	AY	4,526,997	7/2/85	O'Doherty et al.		
RO	AZ	4,468,380	8/28/84	O'Doherty et al.		
RO	BA	4,623,662	11/18/86	De Vries		
RO	BB	4,985,449	1/15/91	Haga et al.		
RO	BC	5,312,820	5/17/94	Ashton et al.		
RO	BD	4,410,697	10/18/83	Török et al.		
RO	BE	4,001,256	1/4/97	Callahan et al.		
RO	BF	5,399,566	3/21/95	Katano et al.		

R0	BG	5,500,424	3/19/96	Nagamine et al.			JC841 U.S. PTO 09/777920 02/07/01
R0	BH	5,597,719	1/28/97	Freed et al.			
R0	BI	4,183,854	1/80	Crossley			
R0	BJ	3,828,001	8/74	Broad et al.			
R0	BK	4,740,520	4/88	Hallenbach et al.			
R0	BL	5,319,099	6/7/94	Kamata et al.			

# **FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
R0	BM	EP 335156	03/11/89	European				X
R0	BN	EP 459887	05/28/91	European				X
R0	BO	EP 371876	11/28/89	European				X
R0	BP	93/24458	12/9/93	WO			X	
R0	BQ	2,146,707	10/12/95	Canada			X	
R0	BR	96/40673	12/19/96	WO			X	
R0	BS	94/14801	07/07/94	WO			X	
R0	BT	94/25012	11/10/94	WO			X	
R0	BU	1,590,870	06/10/81	England			X	
R0	BV	93/18028	09/16/93	WO			X	
R0	BW	94/18170	08/18/94	WO			X	
R0	BX	DE 3305866 A1	02/19/83	Germany				X
R0	BY	95/02591	01/26/95	WO			X	
R0	BZ	95/13067	05/18/95	WO			X	
R0	CA	95/07922	03/23/95	WO			X	
R0	CB	95/31451	11/23/95	WO			X	
R0	CC	A1 96/40675	12/19/96	WO			X	
R0	CD	JP 53 086033	7/29/78	Japan				
R0	CE	JP 51 063170	1/6/76	Japan				
R0	CF	97/49400	12/31/97	WO				
R0	CG	97/49399	12/31/97	WO				
R0	CH	96/40673	12/19/96	WO				
R0	CI	99/00357	1/7/99	WO				
R0	CJ	97/45400	12/4/97	WO				
R0	CK	96/02112	3/8/90	WO				
R0	CL	99/00370	1/7/99	WO				
R0	CM	97/29743	8/21/97	WO				
R0	CN	98/22432	5/28/98	WO				
R0	CO	96/25157 A1	8/22/96	WO				
R0	CP	97/40028 A1	10/30/97	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

R <sub>0</sub>	CQ	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
P	CR	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
R <sub>0</sub>	CS	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
K <sub>1</sub>	CT	"Beilstein number" Collection, 28 pages.
R <sub>0</sub>	CU	"Beilstein Collection," 4 pages.
R <sub>0</sub>	CV	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
R <sub>0</sub>	CX	Substructure Search, pages 1-30.
W	CY	Derwent World Patents Index Search, pages 20-26.
P <sub>1</sub>	CZ	Abstract of EP 116,932
R <sub>0</sub>	DA	Abstract of EP 676,395
R <sub>0</sub>	DB	Abstract of EP 202,538
R <sub>0</sub>	DC	Abstract of EP 16,371
R <sub>0</sub>	DD	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
R <sub>0</sub>	DE	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
R <sub>0</sub>	DF	Audia, James E., et al., "Potent, Selective Tetraphdro-β-carboline Antagonists of the Serotonin 2B (5HT <sub>2B</sub> ) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
R <sub>0</sub>	DG	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT <sub>2B</sub> Receptor Antagonist," March 17, 1995, pages 855-57.
R <sub>0</sub>	DH	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. <sup>1</sup> A Generalised Monocyclic Rearrangement," 1967, 2005-07.
R <sub>0</sub>	DI	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
rel	DJ	G. Daum, et al., The ins and outs of Raf Kinases,:" TIBS 19, November 1994, pages 474-80.
FD	DK	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
R <sub>0</sub>	DL	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype." The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
R <sub>0</sub>	DM	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
R <sub>0</sub>	DN	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
R <sub>0</sub>	DO	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
R <sub>0</sub>	DP	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
R <sub>0</sub>	DQ	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhiibitors," N.Y. Academy of Science, 1993, pages 149-70.
R <sub>0</sub>	DR	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
R <sub>0</sub>	DS	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
R <sub>0</sub>	DT	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.

# U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
RO	DU	5,059,614	10/22/91	Lepage et al.			
RO	DV	3,743,498	7/3/73	Brantley			
RO	DW	3,547,940	12/15/70	Brantley			
RO	DX	5,432,468	7/11/95	Moriyama et al.			
RO	DY	1,742,156	2/31	Fitzky			
RO	DZ	2,046,375	7/36	Goldstein et al.			
RO	EA	2,093,265	9/36	Coffby et al.			
RO	EB	2,288,422	6/42	Rohm			
RO	EC	2,683,082	7/54	Hill et al.			
RO	ED	2,745,874	5/56	Schetty et al.			
RO	EF	2,781,330	2/57	Downey			
RO	EG	2,867,659	1/59	Model et al.			
RO	EH	2,877,268	3/59	Applegate et al.			
RO	EI	2,960,488	11/60	Tamblyn et al.			
RO	EJ	3,689,550	9/72	Schellenbaum et al.			
RO	EK	3,860,645	1/95	Nikawitz			
RO	EL	5,423,905	6/95	Fringeli			
RO	EM	2,973,386	2/61	Weldon			
RO	EN	3,230,141	1/66	Frick et al.			
RO	EO	4,863,924	9/89	Haga et al.			
RO	EP	4,511,571	4/85	Böger et al.			
RO	EQ	4,173,638	11/79	Nishiyama et al.			
RO	ER	4,173,637	11/79	Nishiyama et al.			
RO	ES	4,820,871	4/89	Kissener et al.			
RO	ET	4,983,605	1/91	Kondo et al.			
RO	EU	5,098,907	3/92	Kondo et al.			
RO	EV	5,036,072	7/91	Nakajama et al.			
RO	EW	5,470,882	11/95	Dixon et al.			
RO	EX	5,429,918	7/95	Seto et al.			
RO	EY	3,151,023	9/64	Martin			
RO	EZ	3,200,035	8/65	Martin et al.			
RO	FA	5,807,891	9/15/98	Bold et al.			
RO	FB	4,009,847	3/1/77	Aldrich et al.			



# FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
PS	FC	95/33458	12/14/95	WO				
RD	FD	0 771 333	3/57	Great Britain				
RI	FE	0 921 682	3/63	Great Britain				
RJ	FF	0 253 997	2/88	East Germany				
RK	FG	0 405 233	1/91	Europe				

K <sub>2</sub>	FH	1 457 172	9/66	France			
K <sub>2</sub>	FI	0 487 014	12/29	Germany			
K <sub>2</sub>	FJ	0 511 468	10/30	Germany			
K <sub>2</sub>	FK	0 523 437	5/31	Germany			
K <sub>2</sub>	FL	44 2569	2/69	Japan			
K <sub>2</sub>	FM	55 98152	7/80	Japan			
K <sub>2</sub>	FN	94 22807	10/94	WIPO			
K <sub>2</sub>	FO	3 532 47	3/91	Japan			
K <sub>2</sub>	FP	0 828 231	10/56	Great Britain			
K <sub>2</sub>	FQ	50-149668	11/75	Japan			
K <sub>2</sub>	FR	55-162772	12/80	Japan			
K <sub>2</sub>	FS	60-76072	6/75	Japan			
K <sub>2</sub>	FT	51-80862	7/76	Japan			
K <sub>2</sub>	FU	50-77375	6/75	Japan			
K <sub>2</sub>	FV	55-124763	9/80	Japan			
K <sub>2</sub>	FW	0 502 504 A1	9/92	Europe			
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
K <sub>2</sub>	FX	Tarzia, G. et al. "Whythesis and anti-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.					
K <sub>2</sub>	FY	Appln No. 08/863,021, May 23, 1997, RAF Kinase Inhibitors					
K <sub>2</sub>	FZ	Appln No. 08/863,022, May 23, 1997, RAF Kinase Inhibitors					
<b>Examiner</b> <i>R. Denner</i>					<b>Date Considered</b> <i>12-27-2001</i>		

RJT/lvb  
K:\PAT\Bayer\15P3\1449 2-7-01.wpd

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. BAYER 15P3		SERIAL NO. TO BE ASSIGNED	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Bernd RIEDL			
				FILING DATE February 7, 2001		GROUP TO BE ASSIGNED	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>Ro</i>	AAA	Unassigned, December 22, 1998, Inhibition of RAF Kinase Using Symmetrical Substituted Diphenyl Ureas					
<i>Ro</i>	AAB	Appln No. 09/479,125, December 22, 1998, Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas (Abandoned in favor of Bayer 8C1 Serial No. 09/640,780 filed August 18, 2000)					
<i>Ro</i>	AAC	Appln No. 09/472,232, December 27, 1998, Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas					
<i>Ro</i>	AAD	Appln No. 09/458,015, December 10, 1999, Inhibition of P38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas					
<i>Ro</i>	AAE	Appln No. 09/458,014, December 10, 1999, Inhibition of P38 Kinase Activity Using Substituted Heterocyclic Ureas					
<i>Ro</i>	AAF	Unassigned, December 22, 1998, Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas					
<i>Ro</i>	AAG	Appln No. 09/425,229, October 22, 1999, $\omega$ -Carboxy Aryl Substituted Diphenyl Ureas P38 Kinase Inhibitors					
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner <i>R. D. ...</i>				Date Considered			

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.